PT-141: What It Is, What the Research Says, and What You Need to Know

An FDA-approved melanocortin agonist for sexual dysfunction — available by prescription

Last updated: May 1, 2026

PT-141 is a cyclic heptapeptide that acts on melanocortin receptors in the central nervous system. Its mechanism is fundamentally different from PDE5 inhibitors like sildenafil (Viagra) — it works on the brain rather than on blood vessels.

Originally developed from Melanotan II, PT-141 was isolated for its sexual effects when Melanotan II users reported unexpected increases in sexual arousal.

FDA approved Bremelanotide (Vyleesi) in 2019 specifically for premenopausal women with acquired, generalized HSDD.

• Phase 3 trials for Vyleesi (RECONNECT study) showed significant improvement in sexual desire and reduction in distress related to HSDD in premenopausal women.
• Studies in men show increased erectile function and sexual desire, though it is not FDA-approved for this indication.
• Mechanism is distinct from Viagra — works on brain receptors, not vascular smooth muscle.
• More effective for psychological/desire component of sexual dysfunction.

These reflect how researchers and research communities discuss this compound — not therapeutic recommendations.

• Hypoactive sexual desire disorder (HSDD) in women
• Male sexual dysfunction research
• Sexual motivation and desire enhancement

Activates melanocortin 3 and 4 receptors (MC3R, MC4R) in the brain — particularly in the hypothalamus and limbic system — to increase sexual motivation and arousal through central (brain-based) rather than peripheral (vascular) mechanisms.